Functional Phenotypes of Human Vγ9Vδ2 T Cells in Lymphoid Stress Surveillance.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
22 03 2020
Historique:
received: 14 02 2020
revised: 16 03 2020
accepted: 19 03 2020
entrez: 3 4 2020
pubmed: 3 4 2020
medline: 11 2 2021
Statut: epublish

Résumé

Butyrophilin and butyrophilin-like proteins select γδ T cells and direct the migration of γδ T cell subsets to distinct anatomical sites. γδ T cells expressing Vδ2 paired with Vγ9 (Vγ9Vδ2 T cells) are the predominant γδ T cell type in human peripheral blood. Vγ9Vδ2 T cells, which cannot be studied easily in vivo because they do not exist in rodents, are often referred to as innate-like T cells. The genetically recombined γδ T cell receptor (TCR) that responds to isoprenoid-derived pyrophosphates (phosphoantigens) produced by infected and malignant cells in a butyrophilin-dependent manner qualifies them as therapeutically relevant components of the adaptive immune system. On the other hand, cell-surface proteins such as the C-type lectin CD161 mark a functional phenotype of Vγ9Vδ2 T cells that mediates TCR-independent innate-like responses. Moreover, CD56 (neural cell adhesion molecule, NCAM) and the G protein-coupled receptor GPR56 define Vγ9Vδ2 T cells with increased cytolytic potential and, like CD161, may also be expressed by dendritic cells, principally facilitating the generation of an innate-like immunological synapse. In this review, we summarise current knowledge of Vγ9Vδ2 T cell functional phenotypes that are critical to lymphoid stress surveillance.

Identifiants

pubmed: 32235722
pii: cells9030772
doi: 10.3390/cells9030772
pmc: PMC7140623
pii:
doi:

Substances chimiques

Receptors, Antigen, T-Cell, gamma-delta 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Références

J Immunol. 2011 Feb 15;186(4):2003-12
pubmed: 21239711
Eur J Immunol. 1989 Sep;19(9):1735-9
pubmed: 2477257
J Immunol. 2012 Apr 1;188(7):2972-6
pubmed: 22393149
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7311-E7320
pubmed: 28807997
Clin Immunol. 2004 Oct;113(1):56-63
pubmed: 15380530
J Exp Med. 2000 May 15;191(10):1777-88
pubmed: 10811870
Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):653-7
pubmed: 1346234
Blood. 2009 Nov 12;114(20):4422-31
pubmed: 19762486
Cell Immunol. 2015 Jul;296(1):31-40
pubmed: 25991474
Cell Rep. 2016 Jul 12;16(2):444-456
pubmed: 27346340
J Immunol. 2005 Dec 15;175(12):7791-5
pubmed: 16339512
J Exp Med. 2003 Jan 20;197(2):163-8
pubmed: 12538656
J Exp Med. 2011 Jul 4;208(7):1511-22
pubmed: 21708931
Blood. 2009 Nov 26;114(23):4823-31
pubmed: 19805616
Cell. 1985 Feb;40(2):259-69
pubmed: 3917858
Front Immunol. 2018 Nov 27;9:2760
pubmed: 30538708
Cell Mol Immunol. 2013 Jan;10(1):35-41
pubmed: 23241899
Cell. 2012 Jan 20;148(1-2):244-58
pubmed: 22265415
PLoS One. 2013;8(1):e51805
pubmed: 23326319
Oncoimmunology. 2014 Nov 14;3(8):e953410
pubmed: 25960933
J Immunol. 2019 Jul 15;203(2):311-320
pubmed: 31285310
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):E556-65
pubmed: 25617367
Clin Exp Immunol. 2010 Aug;161(2):290-7
pubmed: 20491785
Nat Rev Cancer. 2007 Feb;7(2):79-94
pubmed: 17251915
Blood. 2011 Jul 7;118(1):129-38
pubmed: 21505189
Biochim Biophys Acta. 2013 Jun;1831(6):1009-15
pubmed: 23524243
J Immunol. 1991 Jun 15;146(12):4421-6
pubmed: 1710251
Mol Cell Biol. 2013 Sep;33(18):3644-58
pubmed: 23858057
Hum Immunol. 1997 Dec;58(2):70-82
pubmed: 9475336
Trends Biochem Sci. 2008 Oct;33(10):491-500
pubmed: 18789697
J Exp Med. 1989 Jun 1;169(6):2233-8
pubmed: 2471777
Blood. 2011 Sep 8;118(10):2743-51
pubmed: 21673342
Nat Commun. 2017 Nov 13;8(1):1473
pubmed: 29133794
J Immunol. 2005 Aug 15;175(4):2144-51
pubmed: 16081780
Cell. 2016 Sep 22;167(1):203-218.e17
pubmed: 27641500
Immunol Rev. 2007 Feb;215:59-76
pubmed: 17291279
Immunity. 2014 Apr 17;40(4):490-500
pubmed: 24703779
Trends Pharmacol Sci. 2006 Feb;27(2):92-6
pubmed: 16406086
Eur J Immunol. 2011 Jan;41(1):195-201
pubmed: 21182090
Blood. 2012 Oct 18;120(16):3271-9
pubmed: 22932792
Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3330-5
pubmed: 21300860
Annu Rev Immunol. 2014;32:121-55
pubmed: 24387714
Immunity. 2009 Aug 21;31(2):184-96
pubmed: 19699170
Nat Immunol. 2018 Dec;19(12):1352-1365
pubmed: 30420626
Int Immunol. 2007 May;19(5):657-73
pubmed: 17446209
Nat Rev Genet. 2010 Jan;11(1):47-59
pubmed: 19997068
Cancer Res. 2010 Dec 1;70(23):9611-20
pubmed: 20947520
Front Cell Dev Biol. 2017 Apr 06;5:34
pubmed: 28428953
Nat Rev Immunol. 2017 Dec;17(12):733-745
pubmed: 28920588
Cell Immunol. 2010;264(1):71-7
pubmed: 20483407
Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12520-12525
pubmed: 27791087
J Immunol. 2008 Feb 1;180(3):1462-70
pubmed: 18209041
Trends Immunol. 2013 Apr;34(4):151-4
pubmed: 23266231
Clin Cancer Res. 2008 Jul 1;14(13):4232-40
pubmed: 18594005
Front Immunol. 2018 Apr 09;9:486
pubmed: 29686665
Front Immunol. 2018 Jun 26;9:1409
pubmed: 29997614
Cell Rep. 2014 Nov 6;9(3):1075-88
pubmed: 25437561
Immunity. 2020 Mar 17;52(3):487-498.e6
pubmed: 32155411
Nature. 2003 Mar 13;422(6928):164-9
pubmed: 12634786
Immunity. 1997 Jan;6(1):1-11
pubmed: 9052832
Nat Rev Immunol. 2015 Dec;15(12):771-83
pubmed: 26567920
J Biol Chem. 2008 May 23;283(21):14469-78
pubmed: 18378689
Trends Immunol. 2016 Oct;37(10):690-702
pubmed: 27567182
Trends Neurosci. 2017 May;40(5):295-308
pubmed: 28359630
Nat Rev Immunol. 2013 Feb;13(2):88-100
pubmed: 23348415
Immunity. 2019 Nov 19;51(5):813-825.e4
pubmed: 31628053
Immunogenetics. 2014 Apr;66(4):243-54
pubmed: 24526346
J Exp Med. 1991 Jun 1;173(6):1331-8
pubmed: 1827825
Science. 2005 Jul 8;309(5732):264-8
pubmed: 15933162
Nat Immunol. 2008 Feb;9(2):146-54
pubmed: 18176566
Clin Cancer Res. 2012 Jul 1;18(13):3524-31
pubmed: 22529099
Trends Cell Biol. 2009 Sep;19(9):455-64
pubmed: 19716304
Blood. 2012 Sep 13;120(11):2269-79
pubmed: 22767497
Oncoimmunology. 2018 Sep 26;8(1):e1522471
pubmed: 30546961
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1039-1044
pubmed: 29339503
J Immunol. 2004 Mar 15;172(6):3573-9
pubmed: 15004158
PLoS One. 2012;7(12):e51851
pubmed: 23284789
J Immunol. 2000 Feb 1;164(3):1148-52
pubmed: 10640724
PLoS One. 2015 Apr 01;10(4):e0123258
pubmed: 25830554
Cancer Res. 2014 Mar 1;74(5):1349-60
pubmed: 24448235
Front Immunol. 2018 Apr 24;9:851
pubmed: 29740448
Annu Rev Immunol. 2000;18:975-1026
pubmed: 10837080
J Immunol. 1994 Sep 15;153(6):2417-28
pubmed: 8077657
Mol Biol Cell. 2004 May;15(5):2375-87
pubmed: 15004227
J Leukoc Biol. 2011 Oct;90(4):735-40
pubmed: 21724806
Front Immunol. 2018 Apr 10;9:658
pubmed: 29692776
Nat Commun. 2017 Jun 05;8:15663
pubmed: 28580927
Blood. 2003 Sep 15;102(6):2310-1
pubmed: 12959943
J Immunol. 2013 Aug 15;191(4):1625-36
pubmed: 23858032

Auteurs

Oliver Nussbaumer (O)

GammaDelta Therapeutics Ltd., The Westworks, 195 Wood Lane, London W12 7FQ, UK.
Peter Gorer Department of Immunobiology, Kings College, London SE1 9RT, UK.

Martin Thurnher (M)

Immunotherapy Unit, Department of Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH